Sino Biopharmaceutical Limited
1177.HK
Below: live stock price for Sino Biopharmaceutical Limited (1177.HK), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Sino Biopharmaceutical Limited (1177.HK) is a Healthcare company based in Hong Kong. Operating in Biotechnology, it employs about 22,838 people. Over the past year 1177.HK traded between 4.19 and 7.48 HKD. Trailing P/E sits near 32.13 on a market cap of about 85.77B HKD. It currently yields 2.90% in dividends.
- Prev close
- $0.62
- Volume (24h)
- $30.26M
- Market cap
- $10.93B
- Currency
- USD (native HKD)
Score
49/ 100 · Mixed
- Value65
- Quality60
- Momentum12
- Growth38
- Risk78
- Dividend44
- Liquidity47
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 0.6147 +0.05%
- +20 bars
- 0.6151 +0.11%
- +60 bars
- 0.6152 +0.14%
- +120 bars
- 0.6152 +0.14%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±3.18% per bar.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: momentum. Price sits near the lower third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value65/100
Value looks solid — driven by P/E (32.13).
P/E:32.13P/B:2.25PEG:0.61 - Quality60/100
Quality looks solid — driven by Gross margin (82.43%).
ROE:14.07%ROA:7.51%Profit margin:7.09%Gross margin:82.43% - Momentum12/100
Momentum looks fragile — driven by 52w change (-32.30%).
52w change:-32.30% - Growth38/100
Growth looks weak — driven by Revenue growth (10.60%).
Revenue growth:10.60%Earnings growth:1.50% - Risk78/100
Risk looks strong — driven by Debt / equity (37.13).
Beta:0.61Debt / equity:37.13 - Dividend44/100
Dividend looks weak — driven by Payout ratio (67.90%).
Dividend yield:2.90%Payout ratio:67.90% - Liquidity47/100
Liquidity looks mixed — driven by Current ratio (1.63).
Current ratio:1.63Quick ratio:1.43
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 247 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 41.3%
- Max drawdown
- -42.2%
- Below period high
- -35.6%
- Best day
- +12.53%
- Worst day
- -6.92%
- Up days
- 39%
- Current streak
- 2 down
- Typical day swing
- 3.9%
- Volume vs average
- -25%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 0.761 high → 0.6004 low · 60 bars
- ResistanceFib +161.8% extensionnot reached1.0208 USD+66.16% from current
- ResistanceFib +100% extensionnot reached0.9216 USD+50.00% from current
- ResistanceFib +61.8% extensionnot reached0.8602 USD+40.01% from current
- ResistanceFib +27.2% extensionnot reached0.8046 USD+30.97% from current
- ResistanceFib 23.6% retracementtested 15×0.7231 USD+17.69% from current
- ResistanceFib 38.2% retracementtested 23×0.6996 USD+13.87% from current
- ResistanceFib 50% midpointtested 13×0.6807 USD+10.79% from current
- ResistanceFib 61.8% retracementtested 7×0.6617 USD+7.70% from current
- ResistanceFib 78.6% retracementNearesttested 9×0.6347 USD+3.31% from current
- Current0.6144 USD
- SupportFib −27.2% extensionnot reached0.5567 USD-9.39% from current
- SupportFib −61.8% extensionnot reached0.5011 USD-18.44% from current
- SupportFib −100% extensionnot reached0.4398 USD-28.42% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $7.48
- 52w low
- $4.19
- 52w change
- -32.30%
- Day high
- $4.94
- Day low
- $4.71
- P/E (TTM)
- 32.13
- Forward P/E
- 15.13
- PEG
- 0.61
- Price / Book
- 2.25
- Beta (5Y)
- 0.61
- Enterprise value
- 89.26B
- EV / Revenue
- 2.65
- EV / EBITDA
- 8.54
- EPS (TTM)
- $0.15
- Forward EPS
- $0.32
- Dividend yield
- 2.90%
- Dividend rate
- $0.14
- Payout ratio
- 67.90%
- Revenue (TTM)
- 33.7B
- EBITDA
- 10.45B
- Free cash flow
- 5.22B
- Total cash
- 27.58B
- Total debt
- 17.17B
- Debt / Equity
- 37.13
- Current ratio
- 1.63
- Quick ratio
- 1.43
- Profit margin
- 7.09%
- Gross margin
- 82.43%
- Return on assets
- 7.51%
- Return on equity
- 14.07%
- Shares outstanding
- 17.79B
- Float
- 8.73B
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.61
- less volatile
- 52-week change
- -32.30%
- Debt / Equity
- 37.13
- very high leverage
- Current ratio
- 1.63
- Quick ratio
- 1.43
- ROE
- 14.07%
- ROA
- 7.51%
- PEG ratio
- 0.61
- EV / Revenue
- 2.65
- EV / EBITDA
- 8.54
- Revenue growth
- 10.60%
- Earnings growth
- 1.50%
- EBITDA
- 10.45B
- Free cash flow
- 5.22B
- Total cash
- 27.58B
- Total debt
- 17.17B
- Insider holdings
- 48.66%
- Institutional
- 23.08%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.